Global Whole Genome and Exome Sequencing Markets Report 2021-2025 - Industry on Verge of Breakout in Healthcare, Consumer and Agricultural Markets
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-Cov-2) 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.
The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered.
Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.
Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?
A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well-funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.
Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
Key Topics Covered:
Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact
Guide for Executives, Marketing, Sales and Business Development Staff
Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 Whole Genome Sequencing Definition In This Report
1.1.1 Whole and Exome Sequencing
1.1.2 Research and Clinical
1.1.3 Clinical Tumor
1.1.4 Clinical Pathogen
1.1.5 Agri/Other
1.1.6 Direct to Consumer
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing
1.5 Sizing the Genome - Not What You Think
1.5.1 Cost, Price and Genome Size, Pricing Practice
1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts
2. Market Overview
2.1 Market Participants Play Different Roles
2.1.1 Instrument Manufacturer
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Sequencing Labs
2.1.10 Audit body
2.2 Whole Genome Sequencing -Markets, Examples and Discussion
2.2.1 Direct to Consumer - Two Approaches
2.2.1.1 The New Age of Medical Information
2.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
2.2.1.3 Newborn and Prenatal - A Brave New World
2.2.1.4 DTC - How Many Segments?
2.2.2 Research Markets
2.2.2.1 Research Funding and Capital Expense
2.2.2.2 WGS Datasets Preferred
2.2.2.3 Existing research repurposed
2.2.2.4 Organism Wide Market
2.2.2.5 Service Suppliers Respond
2.2.3 Clinical - Understanding Germline and Somatic
2.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
2.2.4 Pathogen Testing
2.2.4.1 The Hepatitis C Story
2.2.4.2 Will the Microbiology Department Disappear?
2.2.5 AgriBio - Big Business
2.2.5.1 GMO is Here to Stay
2.2.5.2 WGS Benefits and Risks
2.2.5.3 The New Agriculture
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 Economies of Scale
2.3.3 Instrument Manufacturer Role
2.3.4 Healthcare Industry Impacts - Still Struggling
2.3.4.1 Can the Healthcare Industry Adapt?
2.3.4.2 Genetic Counselling as an Industry
2.3.4.3 WGES Adoption and Cannibalization
2.3.4.4 The Meaning of Grail
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Diagnostic Factors
3.1.2 Interpreting the Code Otherwise
3.1.3 Changes in Agriculture
3.1.4 Fertility Technology Comes of Age
3.1.5 Pathogen Challenges
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs
3.2.3 Healthcare Cost Concerns Curtail Growth
3.2.4 Wellness has a downside
3.2.5 GMO Opposition Movement
3.3 Sequencing Instrumentation
3.3.1 Instrumentation Tenacity
3.3.2 Declining Cost Changes Industry Structure
3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
3.3.4 Illumina
3.3.5 ION
3.3.6 Pacific Biosystems
3.3.7 Roche 454
3.3.8 SOLiD
3.3.9 Oxford Nanopore
3.3.9.1 What is Oxford Nanopore Sequencing?
3.3.9.2 What can Oxford Nanopore Sequencing be used for?
3.3.9.3 Oxford Nanopore Products
3.3.10 Long Reads - Further Segmentation
3.3.11 Linked Reads
3.3.12 Targeted Sequencing Adopts CRISPR
3.3.13 New Sequencing Technologies
3.3.13.1 RNAP sequencing
3.3.13.2 In vitro virus high-throughput sequencing
3.3.13.3 Tunnelling currents DNA sequencing
3.3.13.4 Sequencing by hybridization
3.3.13.5 Sequencing with mass spectrometry
3.3.13.6 Microfluidic Sanger sequencing
3.3.13.7 Microscopy-based techniques
4. WGES Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
Whole-Genome Sequencing Aids Diagnosis in Stockholm
Variantyx Raises $20M in Series C Financing
Nonacus Whole-Genome Sequencing Service for SARS-CoV-2 Testing Laboratories
German Center to Report Polygenic Risk Scores in Clinical Whole-Genome Testing
Stanford Launches Clinical Whole-Genome Sequencing for Cardiovascular Testing
Illumina and New York Healthcare Providers Partner on Clinical WGS
Increased Adoption of WGS Needs Acceptance by Payors, Providers
Veritas Intercontinental Completes €5M Series B Financing Round
M2GEN and Discovery Life Sciences Enter into Agreement for Bioinformatics Support
Services
Genomics England Adopts Quantum ActiveScale Object Storage
GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
NHS Wales Introduces Whole-Genome Sequencing for Critically Ill Newborns
Illumina Achieves First FDA EAU for NGS-Based SARS-CoV-2 Test
C2i Genomics to Launch Trials for MRD Detection Tech
Roche Acquires Sequencing Company Stratos Genomics
UK COVID-19 Sequencing Consortium Launches With £20M in Government, Wellcome Trust
Funding
Invitae Acquires Three Companies: YouScript, Genelex, Diploid
Experience From Centralized Genomic Medicine Lab
MGI to Enable $100 Human Genome
Nebula Genomics offers $299 WGS
Team to Study Campylobacter Omics
Veritas Genetics Restarts US Business
NEOGEN, Gencove partner to advance animal genomics
UK Whole-Genome Sequencing Project Obtains £200M
WGS may help with disease outbreaks
Veritas Cuts WGS Price by 40%
Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
Machine-learning system used to diagnose genetic diseases
Whole Genome Sequencing for healthy creates controversy
100,000 whole genomes sequenced in the NHS
Nebula Genomics Offers FREE Whole Genome Sequencing
5. Profiles of Key Companies
10x Genomics, Inc.
23andME Inc.
Abbott Diagnostics
AccuraGen Inc
Adaptive Biotechnologies
Admera Health, LLC
Agena Bioscience, Inc
Agilent
Akonni Biosystems
Ancestry.com LLC
Anchor Dx
ArcherDx, Inc
ARUP Laboratories
Asuragen
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocept, Inc
Biodesix Inc
BioFluidica
BioGenex
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc
Bio-Techne
C2i Genomics
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Centogene
Chronix Biomedical
Circulogene
Clear Labs
Clinical Genomics
Complete Genomics, Inc. - A BGI Company
Cynvenio
Dante Labs
Datar Cancer Genetics Limited
Day Zero Diagnostics
Diasorin S.p.A
Epic Sciences
Epigenomics AG
Eurofins Scientific
Excellerate Bioscience
Exosome Diagnostics
Fabric Genomics
Fluidigm Corp
Freenome
FUJIFILM Wako Diagnostics
Fujirebio
Fulgent Genetics
GE Global Research
GE Healthcare Life Sciences
Gencove
Genedrive
GeneFirst Ltd.
Genetron Health (Beijing) Co., Ltd
Genewiz
Genomic Health
Genomics England
Genomics Personalized Health (GPH)
GenomOncology
Genzyme Corporation
Grail, Inc.
Grifols
Guardant Health
Guardiome
HeiScreen
Helix
Helomics
Hologic
Horizon Discovery
HTG Molecular Diagnostics
Human Longevity, Inc.
iCellate
Illumina
Incell Dx
Inivata
Invitae Corporation
Invivoscribe
Karius
Macrogen
MDNA Life SCIENCES, Inc
MDx Health
Medgenome
Meridian Bioscience
Mesa Biotech
MIODx
miR Scientific
MNG Labs
Molecular MD
NantHealth, Inc.
Natera
Nebula Genomics
NeoGenomics
New Oncology
Novogene Bioinformatics Technology Co., Ltd.
Omega Bioservices
OncoDNA
OpGen
ORIG3N, Inc.
Origene Technologies
Oxford Nanopore Technologies
Panagene
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
PrecisionMed
Promega
Protagen Diagnostics
Qiagen Gmbh
Quantumdx
Regeneron
Roche Molecular Diagnostics
Roswell Biotechnologies
Seegene
Sequencing.com
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc
SkylineDx
Stratos Genomics
Sure Genomics, Inc.
Sysmex
Sysmex Inostics
Tempus Labs, Inc
Thermo Fisher Scientific Inc.
Veritas Genetics
Volition
6. The Global Market for Whole Genome Sequencing
6.1 Global Market Overview by Country
6.2 Global Market by Application - Overview
6.3 Global Market Organism - Overview
7. Global Whole Genome Sequencing Markets - By Application
7.1 Research
7.2 Clinical Human
7.3 Clinical Tumor
7.4 Clinical Pathogen
7.5 Direct to Consumer
7.6 Agriculture/Other
8. Global Whole Genome Sequencing Markets - by Organism
8.1 Human
8.2 Pathogen
8.3 Other Organism
9. Vision of the Future of Whole Genome Sequencing
For more information about this report visit https://www.researchandmarkets.com/r/z2qzhq
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900